AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Submission of Matters to a Vote of Security Holders

AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Story continues below

Akebia Therapeutics, Inc. (the “Company”) held its 2018 annual meeting of stockholders on June 14, 2018. The stockholders (i)elected three Class I directors to the Board of Directors of the Company (the “Board”) to serve until the 2021 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal, and elected three Class III directors to the Board to serve until the 2020 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal; and (ii)ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

The directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below:

Director

VotesFor VotesWithheld BrokerNon-Votes

Michael D. Clayman

31,620,317 6,056,200 7,718,696

Duane Nash

32,200,119 5,476,398 7,718,696

Ronald C. Renaud, Jr.

32,202,388 5,474,129 7,718,696

John P. Butler

32,521,696 5,154,821 7,718,696

Muneer A. Satter

32,194,988 5,481,529 7,718,696

Michael S. Wyzga

32,202,394 5,474,123 7,718,696

The proposal to ratify the selection of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 received the following votes:

Votes For:

45,142,512

Votes Against:

240,739

Abstentions:

11,962


About AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

An ad to help with our costs